Rationale and design of the cardiac hospitalization atherosclerosis management program at the University of California Los Angeles

American Journal of Cardiology

Volumn 85, Issue 3 SUPPL. 1, 2000, Pages 10-17

  Fonarow, Gregg C ^a   Gawlinski, Anna ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NITRATE; PRAVASTATIN; SIMVASTATIN; TICLOPIDINE;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET; EXERCISE; FOLLOW UP; HEALTH PROGRAM; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART INFARCTION PREVENTION; HOSPITALIZATION; HUMAN; MORTALITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION; STANDARDIZATION; SUDDEN DEATH; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CARDIAC CARE FACILITIES; CHOLESTEROL, LDL; CORONARY DISEASE; DIET THERAPY; EXERCISE THERAPY; HOSPITALIZATION; HOSPITALS, UNIVERSITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOS ANGELES; RESEARCH DESIGN;

EID: 0033960207     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00933-9     Document Type: Article

References (28)

1. American Heart Association. 1999 Heart and Stroke Statistical Update. Dallas: American Heart Association, 1998. (www.amhrt.org/statistics/about.html).
2. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J. Jr, Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the survival and ventricular enlargement trial . N Engl J Med. 327:1992;669-677.
3. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
5. Yusuf S., Sleight P., Held P., McMahon S. Routine medical management of acute myocardial infarction lessons from overviews of recent randomized controlled trials . Circulation. 82:1990;II117-II134.
6. Rossouw J.E., Lewis B., Rifkind B.M. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 323:1990;1112-1119.
7. Krumholz H.M., Radford M.J., Wang Y., Chen J., Heiat A., Marciniak T.A. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction National Cooperative Cardiovascular Project . JAMA. 280:1998;623-629.
8. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 296:1988;320-331.
9. Lonn E.M., Yusuf S., Jha P., Montague T.J., Teo K.K., Benedict C.R., Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90:1994;2056-2069.
10. Smith S.C.J., Blair S.N., Criqui M.H., Fletcher G.F., Fuster V., Gersh B.J., Gotto A.M., Gould K.L., Greenland P., Grundy S.M. AHA consensus panel statement. Preventing heart attack and death in patients with coronary disease. The Secondary Prevention Panel. J Am Coll Cardiol. 26:1995;292-294.
11. Giles W.H., Anda R.F., Jones D.H., Serdula M.K., Merritt R.K., DeStefano F. Recent trends in the identification and treatment of high blood cholesterol by physicians progress and missed opportunities . JAMA. 269:1993;1133-1138.
12. Frolkis J.P., Zyzanski S.J., Schwartz J.M., Suhan P.S. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation. 98:1998;851-855.
13. Sueta C.A., Chowdhury M., Boccuzzi S.J., Smith S.C. Jr, Alexander C.M., Londhe A., Lulla A., Simpson R.J. Jr. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 83:1999;1303-1307.
14. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569-1582.
15. 27th Bethesda Conference. Matching the Intensity of Risk Factor Management with the Hazard for Coronary Disease Events. September 14-15, 1995. J Am Coll Cardiol 1996;27:957-1047.
16. Forrester J.S., Shah P.K. Lipid lowering versus revascularization an idea whose time (for testing) has come . Circulation. 96:1997;1360-1362.
17. Fonarow G.C., Stevenson L.W., Walden J.A., Livingston N.A., Steimle A.E., Hamilton M.A., Moriguchi J., Tillisch J.H., Woo M.A. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 30:1997;725-732.
18. Taylor C.B., Houston-Miller N., Killen J.D., Debusk R.F. Smoking cessation after acute myocardial infarction effects of a nurse-managed intervention . Ann Intern Med. 113:1990;118-123.
19. Bowker T.J., Clayton T.C., Ingham J., McLennan N.R., Hobson H.L., Pyke S.D., Schofield B., Wood D.A. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events) . Heart. 75:1996;334-342.
20. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
21. Van Dis F.J., Keilson L.M., Rundell C.A., Rawstron M.W. Direct measurement of serum low-density lipoprotein cholesterol in patients with acute myocardial infarction on admission to the emergency room. Am J Cardiol. 77:1996;1232-1234.
22. Gore J.M., Goldberg R.J., Matsumoto A.S., Castelli W.P., McNamara P.M., Dalen J.E. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. Am J Cardiol. 54:1984;722-725.
23. Debusk R.F., Miller N.H., Superko H.R., Dennis C.A., Thomas R.J., Lew H.T., Berger W.E. III, Heller R.S., Rompf J., Gee D. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 120:1994;721-729.
24. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
25. Yusuf S., Wittes J., Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 260:1988;2259-2263.
26. Teo K.K., Yusuf S., Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction an overview of results from randomized controlled trials . JAMA. 270:1993;1589-1595.
27. Fonarow G.C., Gawlinski A., Cardin S., Moughirabi S., Tillisch J. Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program CHAMP . Circulation. 96:1997;I67. (Abstr.).
28. Grundy S.M., Balady G.J., Criqui M.H., Fletcher G., Greenland P., Hiratzka L.F., Houston-Miller N., Kris-Etherton P., Krumholz H.M., LaRosa J., Ockene I.S., Pearson T.A., Reed J., Smith S.C.J., Washington R. When to start cholesterol-lowering therapy in patients with coronary heart disease a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction . Circulation. 95:1997;1683-1685.